Mineralys Therapeutics’ (NASDAQ:MLYS – Get Rating) quiet period is set to end on Wednesday, March 22nd. Mineralys Therapeutics had issued 12,000,000 shares in its public offering on February 10th. The total size of the offering was $192,000,000 based on an initial share price of $16.00. During the company’s quiet period, insiders and any underwriters that worked on the IPO are prevented from issuing any earnings forecasts or research reports for the company because of SEC regulations. Following the end of the company’s quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.
Analyst Ratings Changes
A number of brokerages recently commented on MLYS. Stifel Nicolaus initiated coverage on shares of Mineralys Therapeutics in a research note on Tuesday, March 7th. They set a “buy” rating and a $45.00 price target on the stock. Evercore ISI initiated coverage on Mineralys Therapeutics in a research report on Tuesday, March 7th. They set an “outperform” rating on the stock. Wells Fargo & Company began coverage on Mineralys Therapeutics in a research report on Tuesday, March 7th. They set an “overweight” rating and a $27.00 target price on the stock. Bank of America began coverage on Mineralys Therapeutics in a report on Tuesday, March 7th. They set a “buy” rating and a $39.00 target price for the company. Finally, Guggenheim began coverage on Mineralys Therapeutics in a report on Tuesday, March 7th. They set a “buy” rating and a $32.00 target price for the company. Six analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and an average target price of $36.60.
Mineralys Therapeutics Stock Performance
Shares of NASDAQ:MLYS opened at $16.93 on Wednesday. Mineralys Therapeutics has a 52-week low of $15.04 and a 52-week high of $21.98.
Insider Activity at Mineralys Therapeutics
About Mineralys Therapeutics
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. Mineralys Therapeutics Inc is based in RADNOR, Pa.
- Get a free copy of the StockNews.com research report on Mineralys Therapeutics (MLYS)
- Monoclonal Antibodies? Avid Bioservices surges 32% on Blowout Q3
- GitLab Crashes On Guidance; Analysts Defend
- Healthcare Stocks With at Least 30 Years of Dividend Increases
- Coinbase Pops As SVB Crumbles To Dust
- Airlines Update Guidance, Shares Head For Different Destinations
Receive News & Ratings for Mineralys Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mineralys Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.